Current concepts in managing central serous chorioretinopathy

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 45, Issue 1, 2014, Pages 9-13

  Fine, Howard F ^a   Ober, Michael D ^b   Hariprasad, Seenu M ^c  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Retina Consultants of Michigan   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BEVACIZUMAB; EPLERENONE; KETOCONAZOLE; MIFEPRISTONE; RANIBIZUMAB; RIFAMPICIN; STEROID; VASCULOTROPIN INHIBITOR; FINASTERIDE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID RECEPTOR;

ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL OBSERVATION; DIFFERENTIAL DIAGNOSIS; HUMAN; LASER; MULTIMODAL IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE ANGIOGRAPHY; INCIDENCE; LOW LEVEL LASER THERAPY; OBSERVATIONAL METHOD; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT DISORDER; POLYPOIDAL CHOROIDAL VASCULOPATHY; SUBRETINAL FLUID; UVEITIS; DRUG ANTAGONISM; LASER COAGULATION; PHOTOCHEMOTHERAPY; REVIEW; VISUAL SYSTEM EXAMINATION;

ANGIOGENESIS INHIBITORS; CENTRAL SEROUS CHORIORETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; HUMANS; LASER COAGULATION; MULTIMODAL IMAGING; PHOTOCHEMOTHERAPY; RECEPTORS, GLUCOCORTICOID;

EID: 84892614729     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20131220-01     Document Type: Article

References (30)

1. Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: One-year results of a randomized trial [published online ahead of print Nov. 20, 2013]. Ophthalmology. doi: 10.1016/j.ophtha.2013.09.024.
2. Roisman L, Magalhães FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013; 44(5): 465-470.
3. Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y. The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. Ther Clin Risk Manag. 2013; 9: 355-360.
4. Behnia M, Khabazkhoob M, Aliakbari S, Abadi AE, Hashemi H, Pourvahidi P. Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. Retina. 2013; 33(2): 324-328.
5. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012; 56(6): 608-612.
6. Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol. 2012; 12: 20.
7. Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina. 2011; 31(7): 1378-1386.
8. Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011; 152(5): 784-792.
9. Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011; 95(1): 83-88.
10. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010; 24(3): 155-158.
11. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008; 115(10): 1756-1765.
12. Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial. BMC Ophthalmol. 2004; 4: 15.
13. Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA. Acute central serous chorioretinopathy and fundus autofluorescence. Retina. 2005; 25(8): 989-993. (Pubitemid 44735095)
14. Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, Guyer DR, Spaide RF, Maberley D, Wong DW, Slakter JS, Sorenson JA, Fisher YL, Orlock DA. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology. 2000; 107(4): 767-777. (Pubitemid 30191346)
15. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013; 33(8): 1659-1672.
16. Khairallah M, Kahloun R, Tugal-Tutkun I. Central serous chorioretinopathy, corticosteroids, and uveitis. Ocul Immunol Inflamm. 2012; 20(2): 76-85.
17. Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2008; 246(9): 1225-1228.
18. Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica. 2012; 227(2): 85-89.
19. Hassan L, Carvalho C, Yannuzzi LA, et al. Central serous chorioretinopathy in a patient using methylenedioxymethamphetamine (MDMA) or "ecstasy." Retina. 2001; 21: 559-561. (Pubitemid 32971377)
20. Thoelen AM, Bernasconi PP, Schmid C, Messmer EP. Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina. 2000; 20: 98-99. (Pubitemid 30387475)
21. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002; 109: 1834-1837.
22. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003; 23(3): 288-298. (Pubitemid 36792972)
23. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997; 104(4): 616-622. (Pubitemid 27171982)
24. Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review [published online ahead of print Nov. 8 2013]. Eye (Lond). doi: 10.1038/eye.2013.236.
25. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011; 31(9): 1928-1936.
26. Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007; 27(7): 943-946. (Pubitemid 47479391)
27. Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol. 2012; 96(1): 10-13.
28. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina. 2011; 31(4): 766-771.
29. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A Pilot Study. Retina. 2013; 33(10): 2096-2102.
30. John VJ, Mandelcorn ED, Albini TA. Internal drainage for chronic macula-involving serous retinal detachment in idiopathic central serous chorioretinopathy [published online ahead of print Feb. 14, 2013]. Int Ophthalmol. 2013. doi: 10.1007/s10792-013-9731-9.